Switching Between SSRIs (Escitalopram to Fluoxetine)
A direct switch is normally possible when switching from one SSRI to another SSRI. [1] Escitalopram is an “other SSRI” relative to fluoxetine, so discontinuation of escitalopram and initiation of fluoxetine on the next day is generally used. [1][2]
Medication Selection Algorithm
- Direct switch approach (preferred for most SSRI-to-SSRI switches): stop escitalopram and start fluoxetine the following day. [1]
- Cross-taper approach: can be used for some antidepressant transitions, but direct switch is normally possible for SSRI-to-SSRI transitions. [1]
Switching Schedule (Escitalopram to Fluoxetine)
- Day 0: stop escitalopram. [1][2]
- Day 1: start fluoxetine. [1][2]
Monotherapy vs Combination Therapy During the Switch
- Monotherapy during the transition is used with the direct switch strategy. [1]
- Simultaneous administration of both antidepressants is not required with the direct switch strategy. [1][2]
Important Clarifications and Nuances
- The direct switch guidance applies to switching “to another SSRI,” which includes escitalopram → fluoxetine. [1]
- Fluoxetine has a long half-life and can cause drug interactions for weeks after discontinuation of fluoxetine in scenarios where fluoxetine is the drug being stopped. [1]
Initiation Thresholds and Indications
- No washout period is recommended for the escitalopram → fluoxetine transition when using the direct switch strategy. [1]
Common Pitfalls to Avoid
- Delaying the start of fluoxetine beyond the recommended next-day initiation reduces continuity of antidepressant therapy when a direct switch is used. [1][2]
- Using a cross-taper strategy unnecessarily prolongs exposure to two serotonergic agents during the transition when direct switch is normally possible. [1]
Target Outcomes for the Switch
- Symptom control should be reassessed after initiation of fluoxetine to determine the need for dose adjustment or alternative strategies. [2]
References for Switching Strategy Choice
Selection of the switching strategy should incorporate patient-specific tolerability and timing considerations, as guided by structured switching recommendations. [1]